Synopsis: Pico de Coaña and colleagues analyzed peripheral blood from patients undergoing ipilimumab treatment at weeks 0, 3, and 9 and found a sequential decrease in the frequencies of granulocytic MDSC and arginase1-producing CD3-negative cells. At week 9, they found a lower number of Tregs and reduced PD-1 surface expression in CD3-positive cells. 
Synopsis: Regulatory T cells play a central role in tumor escape from immune-mediated rejection. Using a bispecific antibody targeting the tumorspecific mutation of the EGF receptor, EGFRvIII, Choi and colleagues describe a new mechanism they identified by which regulatory T cells can be redirected to elicit potent antitumor activity. To request permission to re-use all or part of this article, contact the AACR Publications Department at
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